• Ep. 63 - Day One's Jeremy Bender: Building Pediatric Oncology from the Ground Up

  • Jun 27 2024
  • Length: 32 mins
  • Podcast

Ep. 63 - Day One's Jeremy Bender: Building Pediatric Oncology from the Ground Up

Listen for free

View show details

  • Summary

  • Pediatric cancer drug development is difficult: it requires high levels of safety, involves parents as well as the patients, and has small populations that can make it difficult to achieve the revenues that reward the investment. Squaring that circle, according to Day One Biopharmaceuticals CEO Jeremy Bender, is not impossible, but takes a dedicated strategy that considers both pediatric and adult development paths from the get-go, and pursues them with equal intensity. In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Bender discussed the rapid rise of Day One, and how it is building a pipeline and evolving a strategy that allows it to keep pediatric drug development central to its philosophy.

    View full story: https://www.biocentury.com/article/652807

    #RandD #DrugDevelopment #pediatriccancer #biopharma #pharma #biotech #lifescience

    00:00 - Intro
    02:25 - Origins & What’s Next
    07:57 - Commercialization & Capital
    15:28 - Precision Pediatric Strategy
    21:00 - First v. Best, ADCs
    30:00 - Life as a CEO
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Show more Show less

What listeners say about Ep. 63 - Day One's Jeremy Bender: Building Pediatric Oncology from the Ground Up

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available